GSK

7 Blue-Chip Dividend Stocks That Are Dead Weight Right Now

By James Brumley, InvestorPlace Feature Writer
Most blue-chip dividend stocks have adjusted for the prospect of rising interest rates, but a few more are facing additional problems.

10 Dangerous High-Yield Dividend Stocks to Avoid

By Brian Bollinger, Simply Safe Dividends
These high-yield dividend stocks could surprise investors with dividend cuts and weak performance. Beware these siren yields!

16 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
The overall ratings of 16 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

13 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
The ratings of 13 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

GlaxoSmithKline plc (ADR) (GSK) Seeks FDA Approval for New Shingles Vaccine

By William White, InvestorPlace Writer
GlaxoSmithKline (GSK), a healthcare company, is seeking approval from the U.S. Food and Drug Administration for a shingles vaccine.

7 Stocks to Sell After Hillary Clinton Wins

By Anthony Mirhaydari, InvestorPlace Market Strategist
Hillary Clinton is the status quo candidate, but she has the biotech industry shaking in their lab coats. Sell these seven healthcare stocks!

11 Pharmaceuticals Stocks to Buy Now

By Portfolio Grader
The grades of 11 Pharmaceuticals stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

7 Dividend Stocks In The Danger Zone

By Brian Nichols, InvestorPlace Contributor
Dividends play a large role in the decisions of some investors, but could be a big risk for these dividend stocks.

4 Pharmaceuticals Stocks to Buy Now

By Portfolio Grader
The grades of 4 Pharmaceuticals stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

Gilead Sciences, Inc. (GILD) Investors Are Drowning in Negativity

By Dan Burrows, InvestorPlace Feature Writer
Gilead Sciences (GILD) stock takes yet another hit as a rival comes after Gilead Sciences' lucrative HIV treatment market.

7 Healthcare Dividend Stocks for Quality and Security

By Aaron Levitt, InvestorPlace Contributor
Looking for great growing dividend stocks? Then these seven healthcare stocks have to be on your buy list.

GSK, GOOGL: GlaxoSmithKline plc (ADR), Alphabet Inc Team Up on Bioelectronics

By William White, InvestorPlace Writer
GlaxoSmithKline (GSK) is teaming up with Alphabet's (GOOG,GOOGL) Verily Life Sciences to form a new company called 'Galvani Bioelectronics.'

7 Things Every Retirement Investor Should Own

By Aaron Levitt, InvestorPlace Contributor
You've put in the work, you should be rewarded for it. These are seven of the best ETFs to get the most from your golden years.

7 Pharmaceuticals Stocks to Buy Now

By Portfolio Grader
This week, 7 Pharmaceuticals stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

This Week’s 43 Biggest Stock Upgrades and Downgrades

By
It pays to stay on top of the latest profit opportunities. Today's post is a great place to start with these updated Portfolio Grader ratings

5 Pharmaceuticals Stocks to Buy Now

By Portfolio Grader
The grades of 5 Pharmaceuticals stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

9 Low-Risk, High-Yield Dividend Stocks to Buy

By Jeff Reeves
Investors need to think about defensive plays with the ability to hang touch in any market, such as these low-risk dividend stocks yielding between 3% and 8%.

Prepare for Earnings Season with These 49 Trades

By
It pays to stay on top of the latest profit opportunities. Today's blog post is a great place to start with these 49 trades to consider

Big Trouble for U.S. Stocks in China

By Lawrence Meyers, InvestorPlace Contributor
Doing business in China can be hazardous to the health of U.S. stocks. Here's a look at just a few of the challenges and risks.
Load More